Medicenna Therapeutics, Inc. is recruiting patients for a PHASE1/PHASE2 clinical trial testing pembrolizumab (Keytruda) for mesothelioma.
The trial, designated NCT05086692, aims to enroll up to 115 participants at 27 sites, including locations in California, Florida, Georgia.
About the Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Treatment Approach
This trial uses a PD-1 checkpoint inhibitor that helps the immune system recognize and attack cancer cells.
Key trial details:
- Phase: PHASE1/PHASE2
- Sponsor: Medicenna Therapeutics, Inc.
- Enrollment target: 115
- Status: RECRUITING
Why This Trial Matters
Study Locations
The trial is recruiting at:
- Sharp Memorial Hospital, California
- UCSF Helen Diller Family Comprehensive Cancer Center, California
- Providence Saint John’s Health Center, California
- Boca Raton Regional Hospital, Florida
- Emory - Winship Cancer Institute, Georgia
How to Enroll
Patients interested in this trial should:
- Discuss eligibility with their oncologist
- Review the full eligibility criteria on ClinicalTrials.gov
- Contact the study coordinator for screening